Authors' reply to Marjoribanks and colleagues, Rossouw and colleagues, Schroll and Lundh, and McPherson

Louise Lind Schierbeck, Lars Køber, Jens‐Erik Beck Jensen
In: BMJ · 2012 · vol. 345(dec03 2) , pp. e8164 · doi:10.1136/bmj.e8164 · W2066181825
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

The authors acknowledge performance and detection bias in open-label trials, particularly for mortality-driven endpoints, and note that no HRT trials in women with a uterus are fully blinded.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

We are grateful for all of the interest in our paper1; more extensive answers are available at bmj.com (www.bmj.com/content/345/bmj.e6409/rr/612351). Although randomisation is an important part of any trial, we acknowledge that performance and detection bias exist in open label trials,2 3 but these biases are less important when endpoints are driven by mortality. Furthermore, no trial of hormone replacement therapy (HRT)—including the Women’s Health Initiative—conducted in women with a uterus is completely blinded.4 5 …

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (7)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK